HRT Financial’s Telix Pharmaceuticals TLX Stock Holding History

HRT Financial’s Portfolio TLX Stock Details TLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-11,641	Closed	-$111K	–	4261
2025 Q3	$111K	Buy	+11,641	New	+$143K	﹤0.01%	2509

Other funds holding TLX

PIC

Portland Investment Counsel Burlington, Ontario, Canada $312M AUM 53.32% 1-Year Est. Return

Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

PAG

Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Quadrature Capital London, United Kingdom $11.7B AUM 87.29% 1-Year Est. Return

Mariner Overland Park, Kansas $85.7B AUM 24.21% 1-Year Est. Return

Vident Advisory Alpharetta, Georgia $11.7B AUM 37.32% 1-Year Est. Return

HRT Financial's TLX Position: Q4 2025 in Review

HRT Financial sold out of Telix Pharmaceuticals (TLX) in Q4 2025, closing a stake of 11,641 shares — an estimated $111K sold.

HRT Financial first reported a position in TLX in Q3 2025 and held it in 1 quarter. The position peaked at $111K in Q3 2025. 40 funds tracked by Wall St. Rank hold TLX as of Q4 2025.

HRT Financial reported no remaining Telix Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
HRT Financial sold 11,641 Telix Pharmaceuticals shares in Q4 2025, an estimated $111K.
HRT Financial first reported a position in Telix Pharmaceuticals in Q3 2025 and held it in 1 quarter.
HRT Financial's Telix Pharmaceuticals position peaked at $111K in Q3 2025.
40 funds tracked by Wall St. Rank held Telix Pharmaceuticals as of Q4 2025.

Based on HRT Financial's 13F filing for Q4 2025, filed 12 Feb 2026.